Developing Central Nervous System and Vulnerability to Platinum Compounds
Figure 2
Cell death and damage of proliferating and differentiating cells at PD17. Bax and Bcl2 immunoreactions. Treatment with dose of 10 μg/g b.w. In comparison with control rats (a, b), an increased labelling for Bax is observed after cisPt (c). Several microglial-like cells, that are labelled for Bax (c, insert: arrows) and Bcl2 (d, insert: arrows), are present in the EGL. The immunoreactivity for Bcl2 in the Purkinje cell bodies (d) is intense. After treatment with PtAcacDMS, Bax (e) and Bcl2 (f) immunoreactivities are similar as in control rats; in particular, some Bcl2 proliferating cells (f, insert: arrows) are detectable in the EGL. Magnification: 40x; insert: 100x.
